HDAC9 and neoplasm: Epigenetic therapies, such as inhibitors of EZH2, LSD1, or HDAC, and hypomethylating agents, can be used to pretreat patients, creatingan inflammatory environment prior to the transfer of T cells by stimulating viral mimicry and increasing expression of antigen presentation by MHC class I on tumor cells.